These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7104169)

  • 41. The disposition and dynamics of labetalol in patients on dialysis.
    Halstenson CE; Opsahl JA; Pence TV; Luke DR; Sirgo MA; Plachetka JR; Abraham PA; Matzke GR
    Clin Pharmacol Ther; 1986 Oct; 40(4):462-8. PubMed ID: 3757409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cimetidine and bioavailability of labetalol.
    Daneshmend TK; Roberts CJ
    Lancet; 1981 Mar; 1(8219):565. PubMed ID: 6111669
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmacodynamics of intravenous labetalol and follow-up therapy with oral labetalol.
    Vlachakis ND; Maronde RF; Maloy JW; Medakovic M; Kassem N
    Clin Pharmacol Ther; 1985 Nov; 38(5):503-8. PubMed ID: 4053487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hemodynamic effects of labetalol in healthy volunteers.
    Allonen H; Kanto J; Pakkanen A; Wendelin H
    Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):517-9. PubMed ID: 7174154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of labetalol and propranolol on human cutaneous vasoconstrictor response to adrenaline.
    Doshi BS; Kulkarni RD; Dattani KK; Anand MP
    Int J Clin Pharmacol Res; 1984; 4(1):25-8. PubMed ID: 6469430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioavailability of medroxalol in man.
    Keeley FJ; Weiner DL; Okerholm RA
    Biopharm Drug Dispos; 1983; 4(4):305-9. PubMed ID: 6661511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Haemodynamic effects of long-term oral labetalol.
    Edwards RC; Raftery EB
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):733-6. PubMed ID: 791328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and pharmacokinetic studies on the alpha- and beta-blocking drug labetalol.
    Kanto J; Allonen H; Lehtonen A; Mäntylä R; Pakkanen A
    Ther Drug Monit; 1980; 2(2):145. PubMed ID: 7052285
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers.
    Rasmussen BB; Larsen LS; Senderovitz T
    BJOG; 2005 Nov; 112(11):1492-9. PubMed ID: 16225568
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rate of onset of hypotensive response with oral labetalol [proceedings].
    Breckenridge AM; Macnee CM; Orme NL; Richards DA; Sterlin MJ
    Br J Clin Pharmacol; 1977 Jun; 4(3):388P. PubMed ID: 901712
    [No Abstract]   [Full Text] [Related]  

  • 51. The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels.
    Agabiti-Rosei E; Alicandri CL; Beschi M; Castellano M; Fariello R; Montini E; Muiesan ML; Romanelli G; Muiesan G
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):87S-92S. PubMed ID: 7093104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of six beta-adrenolytics and labetalol on hepatic biotransformation studied by antipyrine test, in man.
    Adamska-Dyniewska H; Dziekański S; Pruszczyński J
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):303-7. PubMed ID: 2874117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients.
    Svendsen TL; Rasmussen S; Hartling OJ; Nielsen PE; Trap-Jensen J
    Eur J Clin Pharmacol; 1980 Jan; 17(1):5-11. PubMed ID: 7371699
    [No Abstract]   [Full Text] [Related]  

  • 54. Intravenous labetalol in hypertensive patients given by fast and slow injection.
    Pearson RM; Havard CW
    Br J Clin Pharmacol; 1978 May; 5(5):401-5. PubMed ID: 350248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Labetalol.
    Carter BL
    Drug Intell Clin Pharm; 1983 Oct; 17(10):704-12. PubMed ID: 6354658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Use of labetalol in the treatment of hypertensive crises].
    Semplicini A; Pessina AC; Rossi GP; Palatini P; Hlede M; Morandin F; Visonà A; Mazzucato A; Dal Palù C
    G Ital Cardiol; 1982; 12(5):355-8. PubMed ID: 7152187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of labetalol and propranolol on responses to adrenaline infusion in healthy volunteers.
    Doshi BS; Kulkarni RD; Dattani KK; Anand MP
    Int J Clin Pharmacol Res; 1984; 4(1):29-33. PubMed ID: 6469431
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses.
    Rocci ML; Vlasses PH; Cressman MD; Sirgo MA; Plachetka JR
    Pharmacotherapy; 1990; 10(2):92-9. PubMed ID: 2349138
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
    Donnelly R; Macphee GJ
    Clin Pharmacokinet; 1991 Aug; 21(2):95-109. PubMed ID: 1884570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.
    Koch G
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):725-8. PubMed ID: 10950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.